Evidence map›Paper›PMID 36261697›Full record

ArticlePituitary2022

Impact of histopathological classification of non-functioning adenomas on long term outcomes: comparison of the 2004 and 2017 WHO classifications.

Ajay Chatrath, Jacob Kosyakovsky, Parantap Patel, Jungeun Ahn, Mazin Elsarrag, Lena C Young, Angela Wu, Jennifer D Sokolowski, Davis Taylor, John A Jane and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Pituitary, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ajay ChatrathDepartment of Neurological Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Jacob KosyakovskyDepartment of Neurological Surgery, University of Virginia Health System, P.O. Box 800212, Charlottesville, VA, 22908-0711, USA.
Parantap PatelDepartment of Neurological Surgery, University of Maryland, Baltimore, MD, USA.
Jungeun AhnDepartment of Neurological Surgery, University of Virginia Health System, P.O. Box 800212, Charlottesville, VA, 22908-0711, USA.
Mazin ElsarragDepartment of Ophthalmology, MedStar Washington Hospital Center, Washington, DC, USA.
Lena C YoungDepartment of Pathology, University of Virginia Health System, P.O. Box 800214, Charlottesville, VA, 22908-0214, USA.
Angela WuDepartment of Pathology, University of Virginia Health System, P.O. Box 800214, Charlottesville, VA, 22908-0214, USA.
Jennifer D SokolowskiDepartment of Neurological Surgery, University of Virginia Health System, P.O. Box 800212, Charlottesville, VA, 22908-0711, USA.
Davis TaylorNaval Medical Center Portsmouth, Portsmouth, VA, USA.
John A JaneDepartment of Neurological Surgery, University of Virginia Health System, P.O. Box 800212, Charlottesville, VA, 22908-0711, USA. JAJ2K@uvahealth.org.
M Beatriz S LopesDepartment of Neurological Surgery, University of Virginia Health System, P.O. Box 800212, Charlottesville, VA, 22908-0711, USA. msl2e@virginia.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOutcomes of patients with non-functioning pituitary adenomas categorized using the 2004 and 2017 WHO classification systems are understudied. We report outcomes from the University of Virginia of patients with non-functioning pituitary adenomas categorized using both systems.

methodsWe constructed a database from all 239 patients who underwent resection of a non-functioning pituitary adenoma between 2003 and 2015 and had at least 5 years of follow-up. Pathologic diagnosis was determined under both the 2004 and 2017 WHO classification systems. We compared the rates of recurrence and progression between subtypes using univariate and multivariate Cox regression analyses.

resultsNearly 30% of the tumors in our database were classified as null cell adenomas under the 2004 classification system, whereas only 10% of the tumors were classified as null cell adenomas using the 2017 classification system. Most of these tumors were reclassified as either corticotroph or gonadotroph adenomas. Despite our relatively large cohort and average follow-up of nearly 9 years, we did not detect a significant difference in recurrence and progression between subtypes.

conclusionsThe majority of null cell adenomas diagnosed under the 2004 WHO classification system are reclassified as gonadotroph or corticotroph adenomas under the 2017 WHO classification system. Rates of progression and recurrence between subtypes are not as different as previously believed at our institution and require a larger cohort to further investigate.

Indexed as

ACTH-Secreting Pituitary AdenomaAdenomaPituitary NeoplasmsHumansWorld Health OrganizationCorticotroph adenomaGonadotroph adenomaNon-functioning pituitary adenomaNull cell adenoma

Identifiers

PMID36261697

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.